A single dose, globally accessible vaccine to combat emerging SARS-CoV-2 variants

Project Member(s): Hansbro, P.

Funding or Partner Organisation: Medical Research Future Fund (MRFF Coronovirus Scheme)
Medical Research Future Fund (MRFF Coronovirus Scheme)

Start year: 2021

Summary: The emergence of highly transmissible SARS-CoV-2 variants threatens to derail COVID-19 control efforts. We have developed a next-generation vaccine, delivered as a single dose, that targets these variants. In this proposal we willl undertake late-stage pre-clinical testing to determine the optimal vaccine formulation, define protective efficacy against SARS-CoV-2 infection and assess vaccine safety/tolerability. Outcomes will be used to fast track vaccine progression to clinical testing.

FOR Codes: Respiratory diseases , Virology , Infectious Diseases, Respiratory System and Diseases (incl. Asthma), Clinical health

Acknowledgement of Country

UTS acknowledges the Gadigal people of the Eora Nation, the Boorooberongal people of the Dharug Nation, the Bidiagal people and the Gamaygal people, upon whose ancestral lands our university stands. We would also like to pay respect to the Elders both past and present, acknowledging them as the traditional custodians of knowledge for these lands.